DLL3 targeting chimeric antigen receptors and binding agents

MYPI2025004943A0Undetermined Publication Date: 2020-09-01ALLOGENE THERAPEUTICS INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025004943
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-02-04
Filing Date
2020-02-27
Publication Date
2020-09-01
Patent Text Reader

Abstract

Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs. FIGURE 1A
Need to check novelty before this filing date? Find Prior Art